
Jennifer Castriotta
Examiner (ID: 2648, Phone: (571)270-5279 , Office: P/3781 )
| Most Active Art Unit | 3733 |
| Art Unit(s) | 3781, 3733 |
| Total Applications | 769 |
| Issued Applications | 457 |
| Pending Applications | 68 |
| Abandoned Applications | 260 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19729645
[patent_doc_number] => 12207628
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-28
[patent_title] => ADAM6 mice
[patent_app_type] => utility
[patent_app_number] => 17/129706
[patent_app_country] => US
[patent_app_date] => 2020-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 41
[patent_figures_cnt] => 41
[patent_no_of_words] => 43739
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 268
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17129706
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/129706 | ADAM6 mice | Dec 20, 2020 | Issued |
Array
(
[id] => 18193905
[patent_doc_number] => 20230047424
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-16
[patent_title] => GENE THERAPY COMPOSITION AND TREATMENT FOR MYH7-LINKED CARDIOMYOPATHY
[patent_app_type] => utility
[patent_app_number] => 17/783167
[patent_app_country] => US
[patent_app_date] => 2020-12-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10839
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17783167
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/783167 | GENE THERAPY COMPOSITION AND TREATMENT FOR MYH7-LINKED CARDIOMYOPATHY | Dec 8, 2020 | Pending |
Array
(
[id] => 17913506
[patent_doc_number] => 20220315901
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-06
[patent_title] => REPROGRAMMING PROGENITOR COMPOSITIONS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/114888
[patent_app_country] => US
[patent_app_date] => 2020-12-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21060
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17114888
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/114888 | Reprogramming progenitor compositions and methods of use thereof | Dec 7, 2020 | Issued |
Array
(
[id] => 16718300
[patent_doc_number] => 20210085447
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-25
[patent_title] => THREE DIMENSIONAL TISSUE PRINTING DEVICE, THREE DIMENSIONAL TISSUE PRINTING METHOD AND ARTIFICIAL SKIN
[patent_app_type] => utility
[patent_app_number] => 17/110446
[patent_app_country] => US
[patent_app_date] => 2020-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7529
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17110446
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/110446 | THREE DIMENSIONAL TISSUE PRINTING DEVICE, THREE DIMENSIONAL TISSUE PRINTING METHOD AND ARTIFICIAL SKIN | Dec 2, 2020 | Abandoned |
Array
(
[id] => 18700094
[patent_doc_number] => 11786581
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-17
[patent_title] => Directed stem cell recruitment
[patent_app_type] => utility
[patent_app_number] => 17/105156
[patent_app_country] => US
[patent_app_date] => 2020-11-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 28
[patent_no_of_words] => 16443
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 127
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17105156
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/105156 | Directed stem cell recruitment | Nov 24, 2020 | Issued |
Array
(
[id] => 16885692
[patent_doc_number] => 20210171887
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-10
[patent_title] => APPARATUS AND METHOD FOR LEVITATIONAL BIOFABRICATION OF ORGAN AND TISSUE ENGINEERED CONSTRUCTS USING TISSUE SPHEROIDS AND MAGNETOACOUSTIC BIFIELD
[patent_app_type] => utility
[patent_app_number] => 17/094350
[patent_app_country] => US
[patent_app_date] => 2020-11-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9861
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17094350
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/094350 | APPARATUS AND METHOD FOR LEVITATIONAL BIOFABRICATION OF ORGAN AND TISSUE ENGINEERED CONSTRUCTS USING TISSUE SPHEROIDS AND MAGNETOACOUSTIC BIFIELD | Nov 9, 2020 | Abandoned |
Array
(
[id] => 16946730
[patent_doc_number] => 20210205421
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-08
[patent_title] => MESSENGER RNA THERAPY FOR THE TREATMENT OF ORNITHINE TRANSCARBAMYLASE DEFICIENCY
[patent_app_type] => utility
[patent_app_number] => 17/094327
[patent_app_country] => US
[patent_app_date] => 2020-11-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17673
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17094327
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/094327 | Messenger RNA therapy for the treatment of ornithine transcarbamylase deficiency | Nov 9, 2020 | Issued |
Array
(
[id] => 16807876
[patent_doc_number] => 20210130429
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-06
[patent_title] => RECOMBINANT ADENO-ASSOCIATED VIRUS-MEDIATED EXPRESSION OF FRACTALKINE FOR TREATMENT OF NEUROINFLAMMATORY AND NEURODEGENERATIVE DISEASES
[patent_app_type] => utility
[patent_app_number] => 17/081766
[patent_app_country] => US
[patent_app_date] => 2020-10-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14942
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17081766
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/081766 | RECOMBINANT ADENO-ASSOCIATED VIRUS-MEDIATED EXPRESSION OF FRACTALKINE FOR TREATMENT OF NEUROINFLAMMATORY AND NEURODEGENERATIVE DISEASES | Oct 26, 2020 | Abandoned |
Array
(
[id] => 16628963
[patent_doc_number] => 20210047616
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-18
[patent_title] => METHODS AND COMPOSITIONS FOR FEEDER-FREE PLURIPOTENT STEM CELL MEDIA CONTAINING HUMAN SERUM
[patent_app_type] => utility
[patent_app_number] => 17/074481
[patent_app_country] => US
[patent_app_date] => 2020-10-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11917
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 122
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17074481
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/074481 | Methods and compositions for feeder-free pluripotent stem cell media containing human serum | Oct 18, 2020 | Issued |
Array
(
[id] => 16976166
[patent_doc_number] => 20210220403
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-22
[patent_title] => TARGETING THE TUMOR MICROENVIRONMENT USING MANIPULATED NKT CELLS
[patent_app_type] => utility
[patent_app_number] => 17/071511
[patent_app_country] => US
[patent_app_date] => 2020-10-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25082
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17071511
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/071511 | TARGETING THE TUMOR MICROENVIRONMENT USING MANIPULATED NKT CELLS | Oct 14, 2020 | Abandoned |
Array
(
[id] => 16761041
[patent_doc_number] => 20210106622
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-15
[patent_title] => TARGETING THE TUMOR MICROENVIRONMENT USING MANIPULATED NKT CELLS
[patent_app_type] => utility
[patent_app_number] => 17/071507
[patent_app_country] => US
[patent_app_date] => 2020-10-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25057
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17071507
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/071507 | TARGETING THE TUMOR MICROENVIRONMENT USING MANIPULATED NKT CELLS | Oct 14, 2020 | Abandoned |
Array
(
[id] => 16992118
[patent_doc_number] => 20210230538
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-29
[patent_title] => USES OF KINASE INHIBITORS FOR INDUCING AND MAINTAINING PLURIPOTENCY
[patent_app_type] => utility
[patent_app_number] => 17/071627
[patent_app_country] => US
[patent_app_date] => 2020-10-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 63706
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17071627
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/071627 | Uses of kinase inhibitors for inducing and maintaining pluripotency | Oct 14, 2020 | Issued |
Array
(
[id] => 19081868
[patent_doc_number] => 20240108669
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-04
[patent_title] => ADENO-ASSOCIATED VIRUS VECTOR PHARMACEUTICAL COMPOSITION AND METHODS
[patent_app_type] => utility
[patent_app_number] => 17/766941
[patent_app_country] => US
[patent_app_date] => 2020-10-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 83832
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -169
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17766941
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/766941 | ADENO-ASSOCIATED VIRUS VECTOR PHARMACEUTICAL COMPOSITION AND METHODS | Oct 5, 2020 | Pending |
Array
(
[id] => 16778321
[patent_doc_number] => 20210115399
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-22
[patent_title] => METHOD FOR DIFFERENTIATION INDUCTION IN CULTURED STEM CELLS
[patent_app_type] => utility
[patent_app_number] => 17/063139
[patent_app_country] => US
[patent_app_date] => 2020-10-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14395
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17063139
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/063139 | Method for differentiation induction in cultured stem cells | Oct 4, 2020 | Issued |
Array
(
[id] => 16870413
[patent_doc_number] => 20210163880
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => BIOLOGICALLY ACTIVE C-TERMINAL ARGININE-CONTAINING PEPTIDES
[patent_app_type] => utility
[patent_app_number] => 17/039407
[patent_app_country] => US
[patent_app_date] => 2020-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6998
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17039407
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/039407 | BIOLOGICALLY ACTIVE C-TERMINAL ARGININE-CONTAINING PEPTIDES | Sep 29, 2020 | Abandoned |
Array
(
[id] => 16580680
[patent_doc_number] => 20210015082
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-21
[patent_title] => ARTIFICIAL RECOMBINANT CHROMOSOME AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/039784
[patent_app_country] => US
[patent_app_date] => 2020-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57585
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 509
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17039784
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/039784 | ARTIFICIAL RECOMBINANT CHROMOSOME AND USE THEREOF | Sep 29, 2020 | Abandoned |
Array
(
[id] => 19326170
[patent_doc_number] => 12043836
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-23
[patent_title] => RNA-guided endonuclease expressing algal strain for high efficiency in vivo genome editing
[patent_app_type] => utility
[patent_app_number] => 17/039839
[patent_app_country] => US
[patent_app_date] => 2020-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 41
[patent_figures_cnt] => 41
[patent_no_of_words] => 34709
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17039839
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/039839 | RNA-guided endonuclease expressing algal strain for high efficiency in vivo genome editing | Sep 29, 2020 | Issued |
Array
(
[id] => 17830405
[patent_doc_number] => 20220267709
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => PHYSICAL MANIPULATION OF TISSUE CULTURED TISSUE
[patent_app_type] => utility
[patent_app_number] => 17/762316
[patent_app_country] => US
[patent_app_date] => 2020-09-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6495
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 166
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17762316
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/762316 | Physical manipulation of tissue cultured tissue | Sep 21, 2020 | Issued |
Array
(
[id] => 16522893
[patent_doc_number] => 20200396973
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-24
[patent_title] => PSORIASIS-INDUCED ANIMAL MODEL AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/014113
[patent_app_country] => US
[patent_app_date] => 2020-09-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9709
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17014113
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/014113 | PSORIASIS-INDUCED ANIMAL MODEL AND USE THEREOF | Sep 7, 2020 | Abandoned |
Array
(
[id] => 17176814
[patent_doc_number] => 11154041
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-10-26
[patent_title] => Genetically modified non-human animal with human or chimeric genes
[patent_app_type] => utility
[patent_app_number] => 17/010054
[patent_app_country] => US
[patent_app_date] => 2020-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 55
[patent_no_of_words] => 30106
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 110
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17010054
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/010054 | Genetically modified non-human animal with human or chimeric genes | Sep 1, 2020 | Issued |